Table 1.

Different characteristics and schedule of CD20xCD3 bispecific antibody in B-cell lymphomas.

Construct	Format	Technology	Route (Max rec. dose)	Schedule	No. of cycles	Indication	ORR / CR rate % (No. pts)	FDA approval
Mosunetuzumab	IGG1	Knobs-into-Holes (different Fabs)	IV (30 mg)/ SC (45 mg)	SUD: 1 mg C1D1, 2 mg C1D8, 60 mg C1D15, 60 mg C2D1, 30 mg C3D1 + every 21 days	8 cycles if CR – up to 17 cycles if PR or SD	R/R FL ≥ 2 lines of tx	80/60 (90)	Dec 2022
Glofitamab	IGG1	Head-to-tail fusion	IV (30 mg)	Obinutuzumab pretreatment 1000 mg, SUD 2.5 mg C1D8 – 10 mg C1D15 – 30 mg C2D1 every 21 days	Max 12 cycles	R/R DLBCL ≥ 2 lines of tx	56/43 (132)	June 2023
Epcoritamab	IGG1	Controlled Fab-arm exchange	SC (48 mg)	SUD: 0.16 mg C1D1, 0.8 mg C1D8, 48 mg C1D15 once weekly on C1-3, Q 2 weeks C4-9, Q 4 weeks C10+	Until disease progression or toxicity	R/R DLBCL ≥ 2 lines of tx	61/38 (157)	May 2023
Odronextamab	IGG4	Heavy chains with different affinity	IV (320 mg)	0.7 mg split: 0.2 mg C1D1/0.5 mg C1D2, 4 mg split: C1D8/D9, 20 mg split: C1D15/D16, 160 mg C2D1 weekly until C4. 320 mg Q 2 weeks C5+	Until disease progression or toxicity	R/R DLBCL or FL ≥ 2 lines of tx	DLBCL: 49/31 (130) FL: 82/75 (121)	Marketing authorization application EMA
Plamotamab	IGG1	Fab-Fc x scFv-Fc	IV (50 mg)	Cycle 1: 0.8 / 2 / 20 / 35 mg QW Cycle 2: 50 mg QW; Cycle 3 onward: 50 mg Q2W	Until disease progression	Mixed R/R B-NHL	NA	NA
IGM 2323	IGM	IgM + modified J chain	IV (0.5–1000)	Days 1, 8, and 15 of 21-day cycles	Until disease progression	R/R B-NHL	N/A	N/A

Max rec. dose Maximal recommended dose, ORR Overall response rate, CR Complete remission, No. Number, FDA Food and Drug Administration, IV Intravenously, SC Subcutaneously, SUD: Step-up dosing, C Cycle, D Day, PR Partial response, SD Stable disease, R/R Relapsed and/or refractory, DLBCL Diffuse large B cell lymphoma, FL Follicular lymphoma, NHL Non-Hodgkin lymphoma, NA Not applicable, tx Treatment.